Anhui Huaheng

Huaheng Biotechnology is a synthetic biology-focused high-tech company specializing in green value innovation and creation. It develops amino acids, vitamins, and bio-based material monomers for global partners in intermediates, animal nutrition, cosmetics, plant nutrition, and functional foods.

Anhui Huaheng Biotechnology Co’s stock price increases by 2.46% in trading on Monday. The company operates in the biotechnology sector, though no specific catalysts for the rise are detailed in the report.

Nov 2026Global Banking & Finance ReviewNews article

Anhui Huaheng Biotechnology Co., Ltd. reports **CNY 2.38 billion in sales and revenue** for the nine months ended September 30, 2026. This marks an increase from **CNY 2.19 billion** in the same period of the prior year. The company’s financial results reflect growth in its biotechnology operations over the latest quarterly period.

Oct 2026MarketScreenerNews article

Huaheng Biotechnology’s controlling shareholder **Guo Henghua** faces arrest over her alleged role in the collapse of a peer-to-peer (P2P) lending platform nearly a decade ago. The charges derail her company’s planned Hong Kong stock market listing, raising legal and financial uncertainty for Huaheng Biotechnology. Authorities link the case to the broader crackdown on fraudulent lending operations in China’s fintech sector.

Aug 2026Caixin GlobalNews article

Huafeng Biotech founder Guo Henghua was detained by Hefei police on suspicion of illegal deposit-taking and resigned from all company roles. The synthetic biology firm immediately appointed a new chairman and canceled its planned Hong Kong IPO, which had recently cleared regulatory approval.

Jun 2026BigGo FinanceNews article